Andy,> Here come the BROONNNCCCOOS<< Yes, they did. Congratulations & savor the bliss that must be engulfing you now. And to top it off, Bear Stearns feels that the remaining R & D programs {other than the retinoids & rexinoids} & assets " are so substantial, we believe they would constitue an interesting start-up drug discovery company on their own." These include" the company's work on cytokine regulators {small molecules that can stimulate production of natural proteins like Amgen's Epogen}with SKB; signal transduction & inflamation with Abbott; hormonal regulators with AHP {Wyerth}; and metabolic disease modulators with Eli Lilly. On top of this, Glaxo Wellcome is advancing leads identified through a previous cardiovasclar partnership focused mainly on modulators of the LDL cholesterol receptor. The most advanced of these collaborations is LGND's work with AHP on androgen & progestins, which could produce a clinical compound in '98; as with the SERMs, we believe that the identification of more highly selective compounds could embody important commercial worth, as the mechanisms of action have already been proven by existing therapies. " The compounds they included in this category are: Alrt1550 for cancers; alrt268 & ALRT423 both for cancers {LGND} & diabetes & metabolic with LLY; AHP collaboration for hormone responsive cancers, men's & women's health; LLY collaboration for diabetes, obesity, high cholesterol; GLX collaboration for high cholesterol; SBH collaboration for chemotherapy-induced anemia,neutropenia,thrombocytopenia, end-stage renal disease; ABT collaboration for inflammatory diseases. " While these are the important components of LGND's residual programs... {. they } also have a library of retinoids obtained from ALRT, as well as molecules obtained from GLYC that block cellular adhesion."
Lastly, RE the Targretin CTCL program in P3,"Since it is open label, LGND already has a good idea about the response rates generated with Targretin Oral, & the data thus far look very favorable. If, as we expect, data support an NDA, LGND should file such a document during the second half of '98, & could recieve approval for the product in '99."Bernie. |
